EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

YouTube ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò


[Two JAMA articles on overscreening. °úÀ× ¾Ï°ËÁø]

2014³â JAMA 10¿ùÈ£¿¡ overscreening¿¡ ´ëÇÑ µÎ °³ÀÇ ³í¹®ÀÌ ½Ç·È½À´Ï´Ù. µÎ ³í¹® ¸ðµÎ Ÿ ÁúȯÀ¸·Î ±â´ë¿©¸íÀÌ Âª°Å³ª ÃÊ°í·É¿¡¼­´Â ¾Ï°ËÁø Áß´ÜÀ» ±ÇÇÏ°í ÀÖ½À´Ï´Ù.


JAMA 2014;174(10):1558

°í·É, ȤÀº ´Ù¸¥ ÁúȯÀ¸·Î ±â´ë¿©¸íÀÌ ÂªÀº »ç¶÷¿¡¼­´Â ¾Ï°ËÁø Áß´ÜÀÌ ±Ç°íµË´Ï´Ù. ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. º¸Åë 10³â ÀÌ»óÀÇ ±â´ë¿©¸íÀÌ ÀÖÀ» ¶§ ¾Ï°ËÁøÀ» ±ÇÇÏ´Â °ÍÀÌ »ó½ÄÀÔ´Ï´Ù. ±×·¯³ª °¡À̵å¶óÀÎÀÌ Àß ÁöÄÑÁú °Í °°Àº ¹Ì±¹¿¡¼­µµ °¡À̵å¶óÀÎÀº Àß ÁöÄÑÁöÁö ¾Ê°í ÀÖ¾ú½À´Ï´Ù.

¿¬±¸ÀÚµéÀº »ç¸ÁÀ§Çè¿¡ µû¶ó ¾Ï°ËÁøÀÇ ºñÀ²ÀÌ ¾î¶°ÇÑÁö, Áï ±â´ë¿©¸íÀÌ ÂªÀº »ç¶÷¿¡¼­ ¾ó¸¶³ª ¾Ï°ËÁøÀÌ ÀÌ·ç¾îÁö°í ÀÖ´ÂÁö¸¦ ºÐ¼®ÇÏ¿´½À´Ï´Ù. 9³â »ç¸Á À§ÇèÀº NHIS ÀÚ·á¿¡ ±âÃÊÇÏ¿´½À´Ï´Ù (A validated mortality index based on NHIS data,with a C statistic of0.75,wasused tocalculate 9-year mortality risk for each participant. Schonberg 2011). °á°ú´Â ½Ç¸Á½º·¯¿ü½À´Ï´Ù. ±â´ë¿©¸íÀÌ ÂªÀº »ç¶÷¿¡¼­µµ ¾Ï°ËÁøÀÌ ÈçÈ÷ ½ÃÇàµÇ°í ÀÖ¾ú±â ¶§¹®ÀÔ´Ï´Ù.

»ç¸Á À§ÇèÀÌ ¸Å¿ì ³ôÀº »ç¶÷ÀÇ 31% - 55%°¡ ÃÖ±Ù ¾Ï°ËÁøÀ» ¹Þ¾Ò½À´Ï´Ù. ½ÉÁö¾î´Â ÀÚ±ÃÀýÁ¦¼úÀ» ¹ÞÀº »ç¶÷, µû¶ó¼­ ÀڱðæºÎ¾Ï¿¡ °É¸± ¼ö ¾ø´Â »ç¶÷ÀÇ 34% - 56%°¡ ÃÖ±Ù 3³â À̳»¿¡ Pap smear¸¦ ¹Þ¾Ò½À´Ï´Ù. ÀÚ±ÃÀÌ ¾ø´Â ¿©¼º¿¡°Ô ÀÚ±Ã¾Ï °ËÁøÀ̶ó´Ï...

ÀúÀÚ´Â ¾Æ·¡¿Í °°ÀÌ °á·ÐÀ» ¸Î°í ÀÖ½À´Ï´Ù. OverscreeningÀº ºñ¿ëÀ» ÃÊ·¡ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚ¿¡°Ô Çظ¦ Áشٰí...

CONCLUSION: A substantial proportion of the US population with limited life expectancy received prostate, breast, cervical, and colorectal cancer screening that is unlikely to provide net benefit. These results suggest that overscreening is common in both men and women, which not only increases health care expenditure but can lead to net patient harm.



JAMA 2014;174(10);1568

´ëÀå³»½Ã°æ °Ë»ç¿¡´Â ¹Ýµå½Ã ÀÏÁ¤ ¼öÁØÀÇ ÇÕº´ÁõÀÌ ¹ß»ýÇÕ´Ï´Ù. ÃâÇ÷, õ°ø, »ç¸Á µîÀÌ ¸ðµÎ °¡´ÉÇÕ´Ï´Ù. ÇÕº´Áõ ¹ß»ý·üÀº ¾Æ·¡ modeling ±×¸²°ú °°ÀÌ ³ªÀÌ¿¡ µû¶ó Áõ°¡ÇÕ´Ï´Ù.

¿¬±¸ÀÚµéÀº modelingÀ» ÅëÇÏ¿© ´ëÀå³»½Ã°æ °Ë»ç°£°ÝÀ» ´ÜÃàÇϰųª 75¼¼ ÀÌÈÄ¿¡ °Ë»ç¸¦ °è¼ÓÇÏ¿´À» ¶§ µæÀÌ ÀÖ´ÂÁö °ËÅäÇÏ¿´½À´Ï´Ù. °á°ú´Â ¿¹»óÇÑ ±×´ë·Î¿´½À´Ï´Ù. ÀúÀÚ´Â °¡À̵å¶óÀκ¸´Ù ´ëÀå³»½Ã°æ °Ë»ç°£°ÝÀ» ´ÜÃà½ÃÅ°°Å³ª 75¼¼ ÀÌÈÄ¿¡µµ °Ë»çÇÏ´Â °üÇàÀº ÁߴܵǾî¾ß ÇÑ´Ù°í ÁÖÀåÇÏ°í ÀÖ½À´Ï´Ù.


°Ë»ç °£°ÝÀ» ´ÜÃàÇÑ´Ù°í, 75¼¼ ÀÌ»ó±îÁö °Ë»çÇÑ´Ù°í ´õ ¿À·¡ »ç´Â °ÍÀº ¾Æ´Ï¾ú½À´Ï´Ù.


°Ë»ç °£°ÝÀ» ´ÜÃàÇϰųª 75¼¼ ÀÌ»ó±îÁö °Ë»çÇϸé ÇÕº´ÁõÀº ¶Ñ·ÇÇÏ°Ô Áõ°¡µÇ¾ú½À´Ï´Ù.

CONCLUSION: Screening Medicare beneficiaries more intensively than recommended is not only inefficient from a societal perspective; often it is also unfavorable for those being screened. This study provides evidence and a clear rationale for clinicians and policy makers to actively discourage this practice.


JAMA 10¿ùÈ£¿¡ ½Ç¸° µÎ ³í¹®Àº ¹Ì±¹ ÀÇÇа迡¼­ Å« ¹ÝÇâÀ» ÀÏÀ¸Å°°í ÀÖ´Â ¸ð¾çÀÔ´Ï´Ù. ¹Ì±¹ ¼ÒÈ­±âÇÐȸ¿¡¼­ ³»°í ÀÖ´Â GI & Hepatology News¿¡¼­´Â Unnecessary cancer screening 'substantial' in U.S.¶ó´Â Á¦¸ñÀÇ ±â»ç¸¦ headline news·Î »Ì¾Ò½À´Ï´Ù. ÀϺθ¦ ¿Å±é´Ï´Ù.

A substantial proportion of older adults in the United States undergo unnecessary and even harmful screening for colon, prostate, breast, and cervical cancer, contrary to clear guidelines that are widely recognized and well publicized, according to two separate studies published online Aug. 18 in JAMA Internal Medicine.

In the case of colon cancer, most of these unnecessary screenings can be attributed to patients getting rescreened more frequently than at the 10-year intervals recommended and continued screening past the age of 75 years is also a culprit. With the other cancers, the main reason for these unnecessary procedures is continuing screening in patients who have a short life expectancy because of advanced age or irreversible health problems.

In both reports, the investigators emphasized that unnecessary cancer screening is not only inefficient and expensive from a societal perspective but is also harmful for individual patients because it exposes them to invasive procedures and complications, impairs their quality of life, and sometimes leads to downstream overdiagnosis and overtreatment of cancers that would have remained asymptomatic until the patient died of other causes.

(...) Chief among these obstacles is the lack of a simple, reliable tool for assessing life expectancy in clinical practice. In addition, physicians may find it difficult to communicate to patients that they are very likely to die within the next few years, and patients may find it difficult to accept that they have a limited life expectancy or that cancer screening is no longer warranted for them. Physicians¡¯ fear of litigation further contributes to overscreening.

¿ì¸®³ª¶ó¿¡¼­´Â ¾ðÁ¦ overscreening ¹®Á¦°¡ ³íÀÇµÉ ¼ö ÀÖÀ»Áö ´ä´äÇÒ µû¸§ÀÔ´Ï´Ù.


[Âü°íÀÚ·á]

1) EndoTODAY °ÇÁø ³»½Ã°æ